Recent Updates
Recently added Catalysts
LFCR Negative Sentiment Score: 20/100

LIFECORE BIOMEDICAL, INC. (NASDAQ: LFCR) INVESTOR ALERT: Investors With Large Losses in Lifecore Biomedical Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Key Takeaway: Bernstein Liebhard LLP has announced a class action lawsuit on behalf of shareholders of Lifecore Biomedical, Inc. The lawsuit, which encompasses purchases made between October 7, 2020, and March 19, 2024, alleges that Lifecore had deficient internal controls that led to multiple inaccurate financial statements requiring restatement. Affected investors are urged to consider their rights and may contact the law firm for further representation details. Those interested in leading the class have until September 27, 2024, to file necessary papers.

Market Sentiment Analysis

CONCERNS & RISKS

  • Lifecore Biomedical is facing a class action lawsuit due to deficient internal controls over financial reporting.
  • Multiple financial statements from Lifecore were found to be inaccurate and will require restatement.
  • Investors who suffered significant losses are encouraged to seek legal representation.

Full Press Release Details

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Lifecore Biomedical, Inc. (“Lifecore”) (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”).
For more information, submit a form at Lifecore Biomedical, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.
According to the lawsuit, Lifecore maintained deficient internal controls over financial reporting, and issued several financial statements that were inaccurate and would need to be restated.
If you wish to serve as lead plaintiff for the Class, you must file papers by September 27, 2024. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

class action lawsuit

Frequently Asked Questions

What is the Lifecore Biomedical lawsuit about?

The lawsuit claims Lifecore had poor financial reporting controls and issued inaccurate financial statements.

What is the deadline to file as lead plaintiff?

Papers must be filed by September 27, 2024, to become the lead plaintiff.

Do I need to be a lead plaintiff to recover funds?

No, you can share in any recovery without serving as the lead plaintiff.

Are there fees for shareholders in this lawsuit?

All representation is on a contingency fee basis, with no fees for shareholders.

Who can I contact for more information?

You can email Peter Allocco at pallocco@bernlieb.com for more details.

Last updated: Jul 31, 2024